Centaurus Financial Inc. Decreases Stake in Axon Enterprise, Inc $AXON

Centaurus Financial Inc. reduced its position in Axon Enterprise, Inc (NASDAQ:AXON) by 25.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 5,074 shares of the biotechnology company’s stock after selling 1,710 shares during the period. Centaurus Financial Inc.’s holdings in Axon Enterprise were worth $3,642,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Newbridge Financial Services Group Inc. boosted its position in Axon Enterprise by 2.8% during the second quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock worth $421,000 after purchasing an additional 14 shares during the period. Vicus Capital raised its position in shares of Axon Enterprise by 3.7% in the third quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 14 shares during the period. Evergreen Capital Management LLC lifted its stake in shares of Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 15 shares in the last quarter. Blue Trust Inc. lifted its stake in shares of Axon Enterprise by 2.5% during the 3rd quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company’s stock valued at $463,000 after buying an additional 16 shares in the last quarter. Finally, NorthCrest Asset Manangement LLC boosted its holdings in Axon Enterprise by 5.4% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock worth $223,000 after buying an additional 16 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Stronger recurring revenue outlook — analysts and industry write-ups highlight that Axon’s Software & Services segment grew rapidly (~40% y/y in 2025), boosting subscriptions and recurring revenue visibility, which supports higher forward multiples. Axon’s Software & Services Strength in Focus
• Positive Sentiment: Ongoing municipal demand — recent local-government purchases/grants (Decatur $1.97M grant for DPD tech; Yavapai County approves Tasers funding) point to steady device and evidence-management adoption at the municipal level, supporting hardware + services revenue streams. Decatur grant article Yavapai County Tasers
• Positive Sentiment: Institutional interest noted — coverage/mentions (e.g., Baron Capital referenced in investor letters) signal investor interest from growth-focused funds, which can underpin demand for the stock. Baron Capital mention
• Neutral Sentiment: High retail/investor attention — multiple “trending” and comparative performance pieces are circulating, increasing short-term volume and volatility but not signaling a clear directional catalyst. Trending stock write-up
• Neutral Sentiment: Short-interest data appears unreliable — recent reports show “0 shares” and NaN changes, so there’s no actionable signal from the published short-interest figures; treat these data points cautiously.
• Negative Sentiment: Insider sale — Director Erika Nardini sold 198 shares (~$100k) and reduced her stake; while size is modest relative to market cap, insider sales can create short-term negative perception. SEC Form 4
• Negative Sentiment: Recent price weakness and skepticism — coverage (e.g., Forbes) documents a multi-day selloff and questions about whether Axon’s high-growth narrative has paused, which pressures near-term sentiment. Forbes analysis
• Negative Sentiment: Recent intraday/near-term pullbacks reported — some market write-ups note recent declines, adding to short-term volatility risk for momentum-driven holders. Yahoo Markets

Analyst Upgrades and Downgrades

AXON has been the subject of a number of recent research reports. Citigroup reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research report on Monday, December 29th. UBS Group reduced their price target on Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Piper Sandler decreased their price objective on Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Finally, Royal Bank Of Canada dropped their price objective on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a report on Wednesday, February 25th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $762.93.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $508.41 on Thursday. Axon Enterprise, Inc has a 1-year low of $396.41 and a 1-year high of $885.91. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $40.88 billion, a PE ratio of 334.48, a price-to-earnings-growth ratio of 10.81 and a beta of 1.46. The firm’s 50 day simple moving average is $524.40 and its 200 day simple moving average is $603.77.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating the consensus estimate of $1.60 by $0.55. The firm had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same period last year, the firm earned $2.08 EPS. As a group, analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Axon Enterprise news, Director Erika Nardini sold 198 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $506.58, for a total value of $100,302.84. Following the transaction, the director directly owned 1,946 shares in the company, valued at $985,804.68. This represents a 9.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total value of $5,002,400.00. Following the completion of the sale, the chief executive officer directly owned 3,090,997 shares in the company, valued at approximately $1,546,240,339.28. The trade was a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 24,832 shares of company stock worth $13,903,398 over the last three months. Corporate insiders own 4.40% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.